IPO Timeline Raw facts
Broker Deadline
2024-12-16
Morning deadline
HKEX Deadline
2024-12-16
Noon deadline
Broker Results (T-2)
2024-12-17
Some brokers release in afternoon
Grey Market (T-1)
2024-12-18
Afternoon
HKEX Allotment (T-1)
2024-12-18
Evening
Registrar Allotment (T-1)
2024-12-18
Evening
Listing Day (T)
2024-12-19
First day of trading
Company Overview
| Stock Name | Herbs Group |
|---|---|
| Stock Code | 02593 |
| Company Full Name | Herbs Generation Group Holdings Limited |
| Industry | 醫療保健 |
| Principal Activities | 公司是扎根香港超過二十年的多元化保健品及美容與護膚品供應商，采用多渠道銷售模式，專注于開發、銷售及營銷自有品牌產品。 |
| Listing Date | 2024-12-19 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港九龍荔枝角道888號南商金融創新中心6樓A7及A8室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.herbs.hk/ |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 3.75 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 22.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 62,502,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 800 | HK$ 3,000 |
| 2 lots | 1,600 | HK$ 6,000 |
| 3 lots | 2,400 | HK$ 9,000 |
| 4 lots | 3,200 | HK$ 12,000 |
| 5 lots | 4,000 | HK$ 15,000 |
| 6 lots | 4,800 | HK$ 18,000 |
| 7 lots | 5,600 | HK$ 21,000 |
| 8 lots | 6,400 | HK$ 24,000 |
| 9 lots | 7,200 | HK$ 27,000 |
| 10 lots | 8,000 | HK$ 30,000 |
| 15 lots | 12,000 | HK$ 45,000 |
| 20 lots | 16,000 | HK$ 60,000 |
| 25 lots | 20,000 | HK$ 75,000 |
| 30 lots | 24,000 | HK$ 90,000 |
| 35 lots | 28,000 | HK$ 105,000 |
| 40 lots | 32,000 | HK$ 120,000 |
| 45 lots | 36,000 | HK$ 135,000 |
| 50 lots | 40,000 | HK$ 150,000 |
| 75 lots | 60,000 | HK$ 225,000 |
| 100 lots | 80,000 | HK$ 300,000 |
| 125 lots | 100,000 | HK$ 375,000 |
| 150 lots | 120,000 | HK$ 450,000 |
| 175 lots | 140,000 | HK$ 525,000 |
| 200 lots | 160,000 | HK$ 600,000 |
| 225 lots | 180,000 | HK$ 675,000 |
| 250 lots | 200,000 | HK$ 750,000 |
| 375 lots | 300,000 | HK$ 1,125,000 |
| 500 lots | 400,000 | HK$ 1,500,000 |
| 625 lots | 500,000 | HK$ 1,875,000 |
| 750 lots | 600,000 | HK$ 2,250,000 |
| 875 lots | 700,000 | HK$ 2,625,000 |
| 1,000 lots | 800,000 | HK$ 3,000,000 |
| 1,125 lots | 900,000 | HK$ 3,375,000 |
| 1,250 lots | 1,000,000 | HK$ 3,750,000 |
| 1,375 lots | 1,100,000 | HK$ 4,125,000 |
| 1,500 lots | 1,200,000 | HK$ 4,500,000 |
| 1,625 lots | 1,300,000 | HK$ 4,875,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,750 lots | 1,400,000 | HK$ 5,250,000 |
| 1,875 lots | 1,500,000 | HK$ 5,625,000 |
| 2,083 lots | 1,666,400 | HK$ 6,249,000 |
Stock Connect Inclusion
| HK Market Cap | HK$ 165.6M |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | Small Cap Regular Path |
|---|---|
| Est. Threshold | HK$ 10.47B Market cap gap 98% |
| Analysis Result | Market cap below threshold (gap 98%) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | HKD 22.48 million |
| Listing Expenses | ~HK$ 29,700,000 |
| Listing Expenses / Funds Raised | ~22.5% |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 4.14 |
|---|---|
| First Day Open | HK$ 4.69 |
| First Day Change | 10.40% |
| First Day Volume | 58056200.0 |
| First Day Turnover | 268349000.0 |
Use of Proceeds
| Use of Proceeds | 1、約36.4百萬港元（占35.7%）將用作策略營銷及推廣活動，以進一步增強以自有品牌發售的產品的品牌知名度及認可度； 2、約38.6百萬港元（占37.8%）將用作擴大、改善和優化銷售網絡； 3、約4.8百萬港元（占4.7%）將用作擴展并充實產品組合，當中會開發及推出個人用類別新產品以及寵物用類別新產品，并藉改良配方升級現有產品； 4、約12.7百萬港元（占12.4%）將用作招聘人才，其將主要包括(i)招聘及僱用更多產品顧問以支援自營店及品牌體驗中心； 5、約9.5百萬港元（占9.3%）將用作一般營運資金。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
ABCI CAPITAL LIMITED CE AWL249
Overall Coordinators (1)
ABCI Securities Company Limited CE ACX411
Joint Bookrunners (8)
ABCI Securities Company Limited CE ACX411
BOCOM International Securities Limited CE APJ121
Ruibang Securities Limited CE BIJ312
CMBC SECURITIES COMPANY LIMITED CE APU820
Livermore Holdings Limited CE BJN764
SPDB International Capital Limited CE BFZ375
YUE XIU SECURITIES COMPANY LIMITED CE ABQ722
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Lead Managers (16)
ABCI Securities Company Limited CE ACX411
BOCOM International Securities Limited CE APJ121
Ruibang Securities Limited CE BIJ312
CMBC SECURITIES COMPANY LIMITED CE APU820
Livermore Holdings Limited CE BJN764
SPDB International Capital Limited CE BFZ375
YUE XIU SECURITIES COMPANY LIMITED CE ABQ722
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
China Sunrise Securities (International) Limited CE AFS030
Chiyu International Capital Limited CE BJS147
Futu Securities International (Hong Kong) Limited CE AZT137
GET NICE SECURITIES LIMITED CE AAA847
PHILLIP SECURITIES (HONG KONG) LIMITED CE AAG460
Solomon JFZ (Asia) Holdings Limited CE BIF175
SOUTH CHINA SECURITIES LIMITED CE AAA874
ZHESHANG INTERNATIONAL FINANCIAL HOLDINGS CO., LIMITED CE BGD825
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Vital Message Medical Health Care Centre Limited | 4,998,000 HKD | — | 4.00% | — | 6 months | 2025-06-19 |
| 2 | Water Live Wealth Limited | 19,998,000 HKD | — | 16.00% | — | 6 months | 2025-06-19 |
| 3 | 袁子豪 | 3,000,000 HKD | — | 2.40% | — | 6 months | 2025-06-19 |
Directors & Management
| Chairman | 郭致因 |
|---|---|
| Company Secretary | 曾慶煊 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Joy & Love Limited(67.5%),Joy & Faith Limited(7.5%) |
|---|
AI
AI 市场洞察
AI interpretation
deepseek-v4-pro · AI-generated
市场情绪
The Caoji Group IPO saw an extreme oversubscription ratio of 6083.63 times, reflecting overwhelming market enthusiasm. Despite this, the overall hit rate of 30.57% is relatively high, indicating that small applicants benefited from the clawback mechanism and allocation rules. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
申购档位分析
The A-tail (largest A-tier) application of HK$1.3 million had an expected lot allocation of only 0.2016 lots, while the B-head (smallest B-tier) at HK$1.4 million expected 0.2874 lots, a 43% increase for just an extra HK$100,000. This inefficiency suggests that the tier threshold disproportionately favored B-head applicants, making it a more capital-efficient route. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
申购人群画像
Demographic breakdowns such as mainland China participation, gender, or regional distribution were not available for this IPO, possibly due to incomplete reporting or data not yet compiled. Without this information, no conclusions can be drawn about investor composition or concentration trends. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
